Cargando…

Novel potential biomarkers for severe alcoholic liver disease

BACKGROUND: Alcoholic liver disease (ALD) is a leading cause of advanced liver disease; however, minor clinical symptoms in the early stage frequently result in delayed diagnosis and therapy. Invasive liver biopsy, the gold standard for diagnosing ALD, is unsuitable for repetitive analysis. This stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jia, Yu, Jiachi, Wang, Jianan, Liu, Jiayu, Xie, Wei, Li, Ruibing, Wang, Chengbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794087/
https://www.ncbi.nlm.nih.gov/pubmed/36582223
http://dx.doi.org/10.3389/fimmu.2022.1051353
_version_ 1784859963556888576
author Huang, Jia
Yu, Jiachi
Wang, Jianan
Liu, Jiayu
Xie, Wei
Li, Ruibing
Wang, Chengbin
author_facet Huang, Jia
Yu, Jiachi
Wang, Jianan
Liu, Jiayu
Xie, Wei
Li, Ruibing
Wang, Chengbin
author_sort Huang, Jia
collection PubMed
description BACKGROUND: Alcoholic liver disease (ALD) is a leading cause of advanced liver disease; however, minor clinical symptoms in the early stage frequently result in delayed diagnosis and therapy. Invasive liver biopsy, the gold standard for diagnosing ALD, is unsuitable for repetitive analysis. This study aims to identify potential serum biomarkers that could contribute to non-invasive disease screening and monitoring. METHODS: Label-free LC-MS/MS quantitative proteomics analysis was performed to identify differentially expressed proteins in the discovery cohort, followed by bioinformatics analysis based on the KEGG, GO, and String databases. Prioritized proteins were validated subsequently by quantitative assays. The area under the receiver operating characteristic curve (AUROC) was used to assess the diagnosis performance of potential biomarkers. RESULTS: A total of 161 differentially expressed proteins were identified in the discovery cohort, of which 123 were up-regulated and 38 were down-regulated. B2M, IGFALS, and IGFBP3 were evaluated, and all demonstrated excellent diagnosis performance with AUROCs of over 0.9 when distinguishing patients with severe ALD from healthy controls. The AUROC values of B2M, IGFBP3, and IGFALS were 0.7131, 0.8877, and 0.9896 for differentiating severe ALD from non-severe ALD to indicate disease severity. B2M could distinguish patients with non-severe ALD and HC participants with an AUROC value of 0.8985. The efficiency of multiple combinations of these biomarkers was superior to that of the existing liver fibrosis evaluation indices used to monitor disease progression, with AUROC values of over 0.9. IGFALS showed a positive correlation with ALT/AST (r=0.4648, P=0.0009) and may be developed as a therapeutic target. CONCLUSION: This proteomic study identified three novel candidate proteins as promising circulating biomarkers for clinical diagnosis and disease progression and also provided the proteomic atlas for ALD pathophysiological mechanisms.
format Online
Article
Text
id pubmed-9794087
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97940872022-12-28 Novel potential biomarkers for severe alcoholic liver disease Huang, Jia Yu, Jiachi Wang, Jianan Liu, Jiayu Xie, Wei Li, Ruibing Wang, Chengbin Front Immunol Immunology BACKGROUND: Alcoholic liver disease (ALD) is a leading cause of advanced liver disease; however, minor clinical symptoms in the early stage frequently result in delayed diagnosis and therapy. Invasive liver biopsy, the gold standard for diagnosing ALD, is unsuitable for repetitive analysis. This study aims to identify potential serum biomarkers that could contribute to non-invasive disease screening and monitoring. METHODS: Label-free LC-MS/MS quantitative proteomics analysis was performed to identify differentially expressed proteins in the discovery cohort, followed by bioinformatics analysis based on the KEGG, GO, and String databases. Prioritized proteins were validated subsequently by quantitative assays. The area under the receiver operating characteristic curve (AUROC) was used to assess the diagnosis performance of potential biomarkers. RESULTS: A total of 161 differentially expressed proteins were identified in the discovery cohort, of which 123 were up-regulated and 38 were down-regulated. B2M, IGFALS, and IGFBP3 were evaluated, and all demonstrated excellent diagnosis performance with AUROCs of over 0.9 when distinguishing patients with severe ALD from healthy controls. The AUROC values of B2M, IGFBP3, and IGFALS were 0.7131, 0.8877, and 0.9896 for differentiating severe ALD from non-severe ALD to indicate disease severity. B2M could distinguish patients with non-severe ALD and HC participants with an AUROC value of 0.8985. The efficiency of multiple combinations of these biomarkers was superior to that of the existing liver fibrosis evaluation indices used to monitor disease progression, with AUROC values of over 0.9. IGFALS showed a positive correlation with ALT/AST (r=0.4648, P=0.0009) and may be developed as a therapeutic target. CONCLUSION: This proteomic study identified three novel candidate proteins as promising circulating biomarkers for clinical diagnosis and disease progression and also provided the proteomic atlas for ALD pathophysiological mechanisms. Frontiers Media S.A. 2022-12-13 /pmc/articles/PMC9794087/ /pubmed/36582223 http://dx.doi.org/10.3389/fimmu.2022.1051353 Text en Copyright © 2022 Huang, Yu, Wang, Liu, Xie, Li and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Huang, Jia
Yu, Jiachi
Wang, Jianan
Liu, Jiayu
Xie, Wei
Li, Ruibing
Wang, Chengbin
Novel potential biomarkers for severe alcoholic liver disease
title Novel potential biomarkers for severe alcoholic liver disease
title_full Novel potential biomarkers for severe alcoholic liver disease
title_fullStr Novel potential biomarkers for severe alcoholic liver disease
title_full_unstemmed Novel potential biomarkers for severe alcoholic liver disease
title_short Novel potential biomarkers for severe alcoholic liver disease
title_sort novel potential biomarkers for severe alcoholic liver disease
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794087/
https://www.ncbi.nlm.nih.gov/pubmed/36582223
http://dx.doi.org/10.3389/fimmu.2022.1051353
work_keys_str_mv AT huangjia novelpotentialbiomarkersforseverealcoholicliverdisease
AT yujiachi novelpotentialbiomarkersforseverealcoholicliverdisease
AT wangjianan novelpotentialbiomarkersforseverealcoholicliverdisease
AT liujiayu novelpotentialbiomarkersforseverealcoholicliverdisease
AT xiewei novelpotentialbiomarkersforseverealcoholicliverdisease
AT liruibing novelpotentialbiomarkersforseverealcoholicliverdisease
AT wangchengbin novelpotentialbiomarkersforseverealcoholicliverdisease